Biocon Limited is a leading biopharmaceutical company based in Bangalore, India. Founded in 1978 by Kiran Mazumdar-Shaw, Biocon has emerged as a global player in the biotechnology industry with a focus on innovative and affordable healthcare solutions. The company's core business areas include biosimilars, research services, small molecules, and branded formulations.

Biocon's portfolio encompasses a wide range of products and services including insulin analogs, monoclonal antibodies for cancer and autoimmune diseases, immunosuppressants for organ transplants, statins for cardiovascular disease management, and anti-diabetic agents.

The company's pioneering work in biosimilars has garnered international recognition. It was the first Indian firm to receive approval from the US Food and Drug Administration (FDA) for its biosimilar drug - Ogivri (trastuzumab-dkst), used to treat certain breast and stomach cancers. This achievement underscores Biocon's commitment to providing access to high-quality biologics at an affordable cost.

Biocon leverages cutting-edge technology platforms such as fermentation-based manufacturing processes, cell culture technologies, protein purification techniques, formulation development capabilities along with strong research & development facilities to drive innovation across its product offerings.

One key factor that sets Biocon apart from its competitors is its relentless pursuit of excellence through strategic collaborations and partnerships with global pharmaceutical majors like Mylan N.V., Sandoz Inc., Pfizer Inc., Bristol-Myers Squibb Company among others. These alliances have enabled Biocon to expand its market reach while strengthening its position as a reliable supplier of high-quality generic medicines worldwide. In conclusion, Biocon Limited continues to make significant strides towards addressing unmet medical needs globally through their emphasis on scientific expertise combined with technological innovation. Through these efforts coupled with strategic partnerships ensure that it remains at the forefront of delivering accessible healthcare solutions around the world.